Zymeworks (ZYME) Liabilities and Shareholders Equity (2021 - 2026)
Zymeworks recorded quarterly Liabilities and Shareholders Equity of $478.2 million in Q1 2026, up 38.0% quarter-over-quarter from $346.5 million in Q4 2025, and up 12.38% year-over-year from $425.5 million in Q1 2025.
Zymeworks' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $478.2 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 12.38% year-over-year to $478.2 million; the TTM figure through Mar 2026 stood at $1.6 billion (down 13.8% YoY), while the FY2025 annual figure was $346.5 million, down 25.17% from the prior year.
- Liabilities and Shareholders Equity came in at $478.2 million for Q1 2026 at Zymeworks, up from $346.5 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $648.7 million in Q4 2022 to a low of $300.3 million in Q3 2022.
- A 5-year average of $491.0 million and a median of $487.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity jumped 85.29% in 2023 and slipped 25.17% in 2025, its largest moves.
- Zymeworks' Liabilities and Shareholders Equity stood at $648.7 million in 2022, then fell by 10.46% to $580.9 million in 2023, then fell by 20.28% to $463.1 million in 2024, then retreated by 25.17% to $346.5 million in 2025, then soared by 38.0% to $478.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $478.2 million, $346.5 million, and $397.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 478.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 478.22 Mn |
| Dec 31, 2025 | 346.53 Mn |
| Sep 30, 2025 | 397.27 Mn |
| Jun 30, 2025 | 408.39 Mn |
| Mar 31, 2025 | 425.52 Mn |
| Dec 31, 2024 | 463.09 Mn |
| Sep 30, 2024 | 487.15 Mn |
| Jun 30, 2024 | 515.63 Mn |
| Mar 31, 2024 | 553.75 Mn |
| Dec 31, 2023 | 580.88 Mn |
| Sep 30, 2023 | 556.37 Mn |
| Jun 30, 2023 | 602.05 Mn |
| Mar 31, 2023 | 600.74 Mn |
| Dec 31, 2022 | 648.73 Mn |
| Sep 30, 2022 | 300.26 Mn |
| Dec 31, 2021 | 389.13 Mn |